Results 261 to 270 of about 75,785 (301)

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins

Molecular Pharmaceutics, 2019
CD19-targeted chimeric antigen receptor (CAR) T-cells (CAR19s) show remarkable efficacy in the treatment of relapsed/refractory acute lymphocytic leukemia and Non-Hodgkin's lymphoma. However, the use of CAR T-cell therapy against CD19-negative hematological cancers and solid tumors has been challenging.
Justin R Klesmith, Benjamin J Hackel, Paul D Rennert   +2 more
exaly   +3 more sources

CD19 CAR antigen engagement mechanisms and affinity tuning

Science Immunology, 2023
Chimeric antigen receptor (CAR) T cell therapy relies on T cells that are guided by synthetic receptors to target and lyse cancer cells. CARs bind to cell surface antigens through an scFv (binder), the affinity of which is central to determining CAR T cell function and therapeutic success.
Changhao He, Jorge Mansilla-Soto, Nandish Khanra, Mohamad Hamieh, Victor Bustos, Alice J. Paquette, Andreina Garcia Angus, Derek M. Shore, William J. Rice, George Khelashvili, Michel Sadelain, Joel R. Meyerson   +11 more
openaire   +2 more sources

CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy

Leukemia & Lymphoma, 1995
The CD19 antigen plays an important role in clinical oncology. In normal cells, it is the most ubiquitously expressed protein in the B lymphocyte lineage. CD19 expression is induced at the point of B lineage commitment during the differentiation of the hematopoietic stem cell, and its expression continues through preB and mature B cell differentiation ...
R H, Scheuermann, E, Racila
openaire   +2 more sources

A single-cell atlas of CD19 chimeric antigen receptor T cells

Cancer Cell, 2023
Li et al. present a resource of single-cell RNA sequencing (scRNA-seq) data from the infusion products of relapsed or refractory large B cell lymphoma (rrLBCL) patients treated with standard-of-care axicabtagene ciloleucel and identify features that are significantly different between products from responders and non-responders at 3-month followup by ...
Xubin, Li, Jared, Henderson, Max J, Gordon, Irtiza, Sheikh, Loretta J, Nastoupil, Jason, Westin, Christopher, Flowers, Sairah, Ahmed, Linghua, Wang, Sattva S, Neelapu, Paolo, Strati, Qing, Deng, Michael R, Green   +12 more
openaire   +2 more sources

CD19: Lowering the Threshold for Antigen Receptor Stimulation of B Lymphocytes

Science, 1992
Lymphocytes must proliferate and differentiate in response to low concentrations of a vast array of antigens. The requirements of broad specificity and sensitivity conflict because the former is met by low-affinity antigen receptors, which precludes achieving the latter with high-affinity receptors.
R H, Carter, D T, Fearon
openaire   +2 more sources

Donor-derived CD19 chimeric antigen receptor T cells

Current Opinion in Hematology, 2015
As immunotherapy matures into possible front-line therapy, new approaches are necessary to expand the capacity to treat more patients. Although most technologies for chimeric antigen receptor (CAR) therapies require autologous T cells, 'off the shelf' sources are highly desired.Sources of T cells for modification with CARs include cord blood and either
Nathan, Singh, David M, Barrett
openaire   +2 more sources

CD19 Fc-Fusion Protein for Detection of Cells Expressing Anti-CD19 Chimeric Antigen Receptors.

Blood, 2010
Abstract Abstract 3756 Chimeric Antigen Receptors (CARs) consist of the antigen-recognition portion of a monoclonal antibody fused to an intracellular signaling domain that is capable of activating T cells. CARs are displayed on the surface of transduced cells, performing non-MHC-restricted antigen recognition and ...
Satiro N. De Oliveira, Jiexin Wang, Roger P. Hollis, Donald B. Kohn   +3 more
openaire   +1 more source

CD19 regulates B cell antigen receptor-mediated MHC class II antigen processing

Vaccine, 1999
In B cells, the processing of antigens in the context of MHC class II molecules is initiated by the binding of antigen to the B cell antigen receptor (BCR). The BCR serves two roles in antigen processing, signaling for enhanced processing and endocytosing bound antigen.
N M, Wagle, J H, Kim, S K, Pierce
openaire   +2 more sources

Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells

Experimental Hematology, 2007
Preclinical and clinical trials are investigating the potential of T cells genetically modified to express a first-generation CD19-specific chimeric antigen receptor (CAR), designated CD19R, for adoptive immunotherapy of B-lineage leukemias and lymphomas.
Tontanai, Numbenjapon, Lisa M, Serrano, Wen-Chung, Chang, Stephen J, Forman, Michael C, Jensen, Laurence J N, Cooper   +5 more
openaire   +2 more sources

Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes

Immunogenetics, 1992
CD19 is a B lymphocyte cell-surface marker that is expressed early during pre-B-cell differentiation with expression persisting until terminal differentiation into plasma cells. CD19 is a member of the Ig gene superfamily with two extracellular Ig-like domains separated by a non-Ig-like domain, and with an extensive approximately 240 amino acid ...
L J, Zhou, D C, Ord, S A, Omori, T F, Tedder   +3 more
openaire   +2 more sources